Dronabinol - Michael James Enterprises

Drug Profile

Dronabinol - Michael James Enterprises

Latest Information Update: 23 Sep 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator RP Capital Group
  • Developer Michael James Enterprises; University of Illinois at Chicago
  • Class Antiemetics; Appetite stimulants; Cannabinoids; Muscle relaxants; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Sleep apnoea syndrome

Most Recent Events

  • 05 Aug 2016 Michael James Enterprises acquires dronabinol from RP Capital Group
  • 05 Aug 2016 Phase-II clinical trials in Sleep apnoea syndrome in USA (PO) before August 2016
  • 05 Aug 2016 The University of Illinois completes a phase II trial in Sleep apnoea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top